PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Vetter expands its footprint in Asia Pacific region

Vetter, one of the global leaders in prefilled drug-delivery systems, today announced the official opening of a new branch office in South Korea. The new office in Songdo is located within the biologics cluster which is often referred to as a ‘sweet spot’ by the industry as it houses numerous prominent biopharmaceutical companies and service providers.
 
Strengthening its global footprint in the Asia Pacific (APAC) region has been an ongoing goal for Vetter. The company established its APAC hub in Singapore in 2014, and subsequently formed a Japanese subsidiary by opening an office in Tokyo in 2015. Although the pharmaceutical service provider had already been active in the South Korean market for years, the establishment of its own local branch office underlines the company’s commitment to the Asia Pacific market, particularly South Korea. With the new footprint, Vetter will be better positioned to support its existing South Korean business as well as that of new local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.
 
“Today is yet another milestone for our company. This new office will allow us to directly serve both local and global companies with South Korean market interests,” said Vetter Managing Director Peter Soelkner. “We are certain that our market presence and activities in this market will serve as an additional base and contribution for Vetter’s future global organic growth.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026